Qianhong Pharmaceutical on Aug 7 reported 1H 2026 revenue of 758 mln yuan, down
12% YoY, and net profit attributable to shareholders of 153 mln yuan, down
40.78% YoY; basic EPS 0.1215 yuan. The company cited sustained weak global
demand for heparin APIs and concurrent price and volume declines, together with
a pressured global pharmaceutical environment, as driving continued falls in
overseas sales.
